Magnetic resonance imaging biomarkers of ischemic stroke: Criteria for the validation of primary imaging biomarkers

Drug News and Perspectives

Volumn 22, Issue 8, 2009, Pages 481-486

  Pedraza, Salvador ^a,b   Puig, Josep ^a   Blasco, Gerard ^a   Daunis i Estadella, Josep ^c   Boada, Lmma ^c   Bardera, Anton ^c   Prats, Alberto ^d   Castellanos, Mar ^a   Serena, Joaquín ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANGIOGRAPHY; BLEEDING; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; DIFFUSION WEIGHTED IMAGING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; STROKE; VALIDATION STUDY; VASCULAR PATENCY;

BIOLOGICAL MARKERS; BRAIN ISCHEMIA; HUMANS; MAGNETIC RESONANCE IMAGING; STROKE; VALIDATION STUDIES AS TOPIC;

EID: 76049109267     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.8.1413791     Document Type: Review

References (62)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333(24): 1581-7.
2. Castellanos, M. and Serena, J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 2007, 24(Suppt. 1): 7-15.
3. Merrill, R.A. The architecture of government regulation of medical products. Va Law Rev 1996, 82: 1753-866.
4. Saver, J.L. Proposal for a universal definition of cerebral infarction. Stroke 2008, 39(11): 3110-5.
5. FDA Modernization Act of 1997. Pub L No. 105-114, 111 Stat 2296, 21 USC §301-94.
6. Castellanos, M., Sobrino, T., Pedraza, S. et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008, 71(23): 1862-8.
7. Jensen, M.B., Chacon, M.R., Sattin, J.A., Levine, R.L. and Vemuganti, R. Potential biomarkers for the diagnosis of stroke. Expert Rev Cardiovasc Ther 2009, 7(4): 389-93.
8. Whiteley, W., Chong, W.L., Sengupta, A. and Sandercock, P. Blood markers for the prognosis of ischemic stroke: A systematic review. Stroke 2009, 40(5): e380-9.
9. Prentice, R.L. Surrogate markers in clinical trials: Definitions and operations criteria. Stat Med 1989, 8: 431-40.
10. Fleming, T.R. and DeMets, D.L. Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 1996, 125(7): 605-13.
11. Pedraza, S., Puig, J., Remollo, S., Quiles, A., Gomez, E., Laguillo, G. and Blasco, G. Magnetic resonance imaging in the diagnosis of stroke. Expert Opin Med Diagn 2008, 2(7): 1-10.
12. Provenzale, J.M. and Wintermark, M. Optimization of perfusion imaging for acute cerebral ischemia: Review of recent clinical trials and recommendations for future studies. AJR Am J Roentgenol 2008, 191(4): 1263-70.
13. Wintermark, M., Flanders, A.E., Velthuis, B. et al. Perfusion-CT assessment of infarct core and penumbra. Receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006, 37(4): 979-85.
14. Martin-Ventura, J.L., Blanco-Colio, L.M., Tuñón, J. et al. Biomarkers in cardiovascular medicine. Rev Esp Cardiol 2009, 62(6): 677-88.
15. Schatzkin, A. and Gail, M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2002, 2(1): 19-27.
16. Del Zoppo, G.J., Poeck, K., Pessin, M.S. et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992, 32(1): 78-86.
17. Röther, J., Schellinger, P., Gass, A. et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002, 33(10): 2438-45.
18. Hacke, W., Albers, G., Al-Rawi, Y. et al. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36(1): 66-73.
19. Hacke, W., Furtan, A.J., At-Rawi, Y. et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009, 8(2): 141-50.
20. Furlan, A.J., Eyding, D., Albers, G.W. et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006, 37(5): 1227-31.
21. Albers, G.W., Thijs, V.N., Wechsler, L. et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006, 60(5): 508-17.
22. Olivot, J.M., Mlynash, M., Thijs, V.N. et al. Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE. Insights from RADAR. Stroke 2009, 40(5): 1692-7.
23. Wintermark, M., Sesay, M., Barbier, E. et al. Comparative overview of brain perfusion imag ing techniques. Stroke 2005, 36(9): 2032-3.
24. Davis, S.M., Donnan, G.A., Parsons, M.W. et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial. Lancet Neurol 2008, 7(4): 299-309.
25. Astrup, J., Siesjo, B.K. and Symon, L. Thresholds in cerebral ischemia - The ischemic penumbra. Stroke 1981, 12(6): 723-5.
26. Hossmann, K.A. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994, 36(4): 557-65.
27. Furlan, M., Marchai, G., Viader, F., Derlon, J.M. and Baron, J.C. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996, 40(2): 216-26.
28. Warach, S., Pettigrew, L.C., Dashe, J.F. et al. Citicoline 010 Investigators. Effect of citicoline on ischemic lesions as measured by diffusion weighted magnetic resonance imaging. Ann Neurol 2000, 48(5): 713-22.
29. Shih, L.C., Saver, J.L., Alger, J.R. et al. Perfusion-weighted magnetic resonance imaging thresholds identifying core, irreversibly infarcted tissue. Stroke 2003, 34(6): 1425-30.
30. Warach, S., Gaa, J., Siewert, B., Wielopolski, P. and Edelman, R.R. Acute human stroke studled by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995, 37(2): 231-41.
31. Moseley, M.E., Kucharczyk, J., Mintorovitch, J. et al. Diffusion-weighted MR imaging of acute stroke: Correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol 1990, 11(3): 423-9.
32. Hjort, N., Christensen, S., Sølling, C. et al. Ischemic injury detected by diffusion imaging 11 minutes after stroke. Ann Neurol 2005, 58(3): 462-5.
33. Ebinger, M., Iwanaga, T., Prosser, J.F. et al. Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke. Stroke 2009, 40(7): 2572-4.
34. Davalos, A., Blanco, M., Pedraza, S. et al. The clinical-DWI mismatch: A new diagnostic approach to the brain tissue at risk of infarction. Neurology 2004, 62(12): 2187-92.
35. Lansberg, M.G., Thijs, V.N., Hamilton, S., chlaug, G., Bammer, R., Kemp, S. and Albers, G.W. Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE. Stroke 2007, 38(6): 1826-30.
36. Lansberg, M.G., Thijs, V.N., Bammer, R. et al. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke 2008, 39(9): 2491-6.
37. Larrue, V., von Kummer, R., Muller, A. and Bluhmki, E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001, 32(2): 438-41.
38. Hacke, W., Donnan, G., Fieschi, C. et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363(9411): 768-74.
39. Olivot, J.M., Mlynash, M., Thijs, V.N. et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke 2008, 39(8): 2257-63.
40. Lansberg, M.G., Thijs, V.N., Bammer, R., Kemp, S., Wijman, C.A.C., Marks, M.P. and Albers, G.W. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007, 38(8): 2275-8.
41. Rivers, C.S., Wardlaw, J.M., Armitage, P.A. et al. Do acute diffusion- and perfusion-weighted MRI lesions identify final infarct volume in ischemic stroke? Stroke 2006, 37(1): 98-104.
42. Beaulieu, C., de Crespigny, A., Tong, D.C., Moseley, M.E., Albers, G.W. and Marks, M.P. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: Evolution of lesion volume and correlation with clinical outcome. Ann Neurol 1999, 46(4): 568-78.
43. Kidwell, C.S., Saver, J.L., Mattiello, J. et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000, 47(4): 462-9.
44. Rother, J., de Crespigny, A.J., D'Arceuil, H., Iwai, K. and Moseley, M.E. Recovery of apparent diffusion coefficient after ischemia-induced spreading depression relates to cerebral perfusion gradient. Stroke 1996, 27(5): 980-6.
45. Olivot, J.M., Mlynash, M., Thijs, V.N. et al. Geography, structure, and evolution of diffusion and perfusion lesions in diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE). Stroke 2009, 40(10): 3245-51.
46. Schellinger, P.D. EPITHET: Failed chance or new hope? Lancet Neurol 2008, 7(4): 286-7.
47. Sobesky, J., Weber, O.Z., Lehnhardt, F.G., Hessetmann, V., Neveling, M., Jacobs, A. and Heiss, W.D. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke 2005, 36(5): 980-5.
48. Parsons, M.W., Yang, Q., Barber, P.A. et al. Perfusion magnetic resonance imaging maps in hyperacute stroke: Relative cerebral blood flow most accurately identifies tissue destined to infarct. Stroke 2001, 32(7): 1581-7.
49. Thijs, V.N., Adami, A., Neumann-Haefelin, T., Moseley, M.E., Marks, M.P. and Albers, G.W. Relationship between severity of MR perfusion deficit and DWI lesion evolution. Neurology 2001, 57(7): 1205-11.
50. Takasawa, M., Jones, P.S., Guadagno, J.V. et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke 2008, 39(3): 870-7.
51. Olivot, J.M., Mlynash, M., Thijs, V. et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke 2009, 40(2): 469-75.
52. Hjort, N., Butcher, K., Davis, S.M. et al. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 2005, 36(2): 388-97.
53. Donnan, G.A. and Davis, S.M. Life after DIAS II. Int J Stroke 2007, 2(4): 236-7.
54. Kane, I., Sandercock, P. and Wardlaw, J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: A systematic review of the evidence to date. J Neurol Neurosurg Psychiatry 2007, 78(5): 485-91.
55. Kane, I., Carpenter, T., Chappell, F., Rivers, C., Armitage, P., Sandercock, P. and Wardlaw, J. Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke: Effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. Stroke 2007, 38(12): 3158-64.
56. Schellinger, P.D. and Kohrmann, M. MRA/DWI mismatch: A novel concept or something one could get easier and cheaper? Stroke 2008, 39(9): 2423-4.
57. Fiehler, J., Alberrs, G.W., Boulanger, J.M. et al. Bleeding risk analysis in stroke imaging before thrombolysis (BRASIL): Pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 2007, 38(10): 2738-44.
58. Kim, E.Y., Na, D.G., Kim, S.S., Lee, K.H., Ryoo, J.W. and Kim, H.K. Prediction of hemorrhagic transformation in acute ischemic stroke: Role of diffusion-weighted imaging and early parenchymal enhancement. Am J Neuroradiol 2005, 26(5): 1050-5.
59. Warach, S. and Latour, L.L. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004, 35(11, Suppl. 1): 2659-61.
60. Oppenheim, C., Samson, Y., Dormont, D. et al. DWI prediction of symptomatic hemorrhagic transformation in acute MCA infarct. J Neuroradiol 2002, 29(1): 6-13.
61. Alsop, D.C., Makovetskaya, E., Kumar, S., Selim, M. and Schlaug, G. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke 2005, 36(4): 746-50.
62. Wintermark, M., Albers, G.W., Alexandrov, A.V. et al. Acute stroke imaging research roadmap. Stroke 2008, 39(5): 1621-8.